Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
6.23B | 6.07B | 5.83B | 5.25B | 4.63B | Gross Profit |
3.73B | 3.59B | 3.36B | 3.01B | 2.61B | EBIT |
1.21B | 1.13B | 987.40M | 812.80M | 539.40M | EBITDA |
1.67B | 1.57B | 1.47B | 1.21B | 947.80M | Net Income Common Stockholders |
832.90M | 865.80M | 755.20M | 608.40M | 1.61B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
813.30M | 1.89B | 709.20M | 819.30M | 2.94B | Total Assets |
17.02B | 16.91B | 15.89B | 16.47B | 16.05B | Total Debt |
3.71B | 3.81B | 3.25B | 4.14B | 4.43B | Net Debt |
2.89B | 1.92B | 2.54B | 3.32B | 2.61B | Total Liabilities |
6.82B | 6.59B | 6.20B | 6.95B | 7.08B | Stockholders Equity |
10.19B | 10.32B | 9.68B | 9.51B | 8.96B |
Cash Flow | Free Cash Flow | |||
1.41B | 1.25B | 1.21B | 911.10M | 1.36B | Operating Cash Flow |
1.53B | 1.35B | 1.30B | 961.10M | 1.44B | Investing Cash Flow |
-1.80B | -195.40M | -102.50M | -2.62B | -148.40M | Financing Cash Flow |
-792.70M | 32.30M | -1.27B | 652.00M | -696.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $38.17B | 20.42 | 11.33% | 1.79% | 1.23% | -58.22% | |
74 Outperform | $21.77B | 26.98 | 8.61% | ― | 2.98% | -5.64% | |
71 Outperform | $23.69B | 29.52 | 8.12% | 0.46% | 2.75% | -2.90% | |
71 Outperform | $24.87B | 41.22 | 12.22% | ― | -6.07% | -35.80% | |
67 Neutral | $14.66B | 10.07 | 29.37% | ― | -3.04% | 388.42% | |
59 Neutral | $10.65B | 10.45 | -6.56% | 3.01% | 7.31% | -12.18% | |
51 Neutral | $9.97B | ― | 0.88% | ― | 14.61% | 85.44% |
On February 26, 2025, Fortive Corporation expanded its Board of Directors from nine to ten members, appointing Gregory J. Moore, M.D., Ph.D., as a new board member. Dr. Moore will also serve on the Compensation Committee and Nominating and Governance Committee, receiving the same compensation as other non-employee directors. His appointment highlights Fortive’s commitment to strengthening its governance and leadership structure, with Dr. Moore being recognized as an independent director under NYSE standards.